Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2018

  • ID: 4599974
  • Report
  • 87 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Insys Therapeutics Inc
  • LG Chem Ltd
  • Millendo Therapeutics Inc
  • OptiNose US Inc
  • Saniona AB
  • Soleno Therapeutics Inc
  • MORE
Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2018, provides an overview of the Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline landscape.

Prader-Willi Syndrome (PWS) is a rare genetic disorder present at birth that results in a number of physical, mental and behavioral problems. PWS is due to lack of several genes on one of an individual’s two chromosome 15’s. In the majority of cases, there is a deletion. In remaining cases, the entire chromosome from the father is missing and there are instead two chromosome 15’s from the mother (uniparental disomy). Symptoms include poor muscle tone, low levels of sex hormones and a constant feeling of hunger.

Report Highlights:

This latest pipeline guide Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Prader-Willi Syndrome (PWS) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Prader-Willi Syndrome (PWS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 6, 3, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Prader-Willi Syndrome (PWS) (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Prader-Willi Syndrome (PWS) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Prader-Willi Syndrome (PWS) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Prader-Willi Syndrome (PWS) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Prader-Willi Syndrome (PWS) (Genetic Disorders)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Prader-Willi Syndrome (PWS) (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Insys Therapeutics Inc
  • LG Chem Ltd
  • Millendo Therapeutics Inc
  • OptiNose US Inc
  • Saniona AB
  • Soleno Therapeutics Inc
  • MORE
Introduction

Report Coverage

Prader-Willi Syndrome (PWS) - Overview

Prader-Willi Syndrome (PWS) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Prader-Willi Syndrome (PWS) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Prader-Willi Syndrome (PWS) - Companies Involved in Therapeutics Development

Chong Kun Dang Pharmaceutical Corp

ConSynance Therapeutics Inc

Ferring International Center SA

Insys Therapeutics Inc

LG Chem Ltd

Millendo Therapeutics Inc

OptiNose US Inc

Saniona AB

Soleno Therapeutics Inc

Zafgen Inc

Prader-Willi Syndrome (PWS) - Drug Profiles

(metoprolol + tesofensine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZP-531 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

beloranib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cannabidiol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

carbetocin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSTI-500 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

diazoxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

diazoxide choline CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GLWL-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-04 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IGO-067 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxytocin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxytocin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RM-853 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

setmelanotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate snRNP-N for Prader-Willi Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Glycogen Synthase for Prader Willi Syndrome and Glycogen Storage Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

somatropin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZGN-1258 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Prader-Willi Syndrome (PWS) - Dormant Projects

Prader-Willi Syndrome (PWS) - Discontinued Products

Prader-Willi Syndrome (PWS) - Product Development Milestones

Featured News & Press Releases

Jul 09, 2018: Zafgen and the Foundation for Prader-Willi Research Announce PATH for PWS Natural History Study

Jun 21, 2018: Levo Therapeutics Announces Publication of Phase 2 Study Results and Planned Phase 3 Study of Intranasal Carbetocin for the Treatment of Prader-Willi Syndrome

Jun 11, 2018: Saniona plans Phase 2a study for treatment of Hypothalamic Obesity

Jun 05, 2018: Saniona reports positive results from preclinical studies for Tesomet opening op for long-term clinical studies

May 29, 2018: Saniona reports positive results from Phase 1 study with new Tesomet tablet

May 14, 2018: Soleno Therapeutics Announces Initiation of Phase III Clinical Trial of DCCR in Prader-Willi Syndrome

Apr 27, 2018: INSYS Therapeutics Initiates Phase 2 Clinical Trial of Cannabidiol (CBD) for Treatment of Prader-Willi Syndrome

Apr 26, 2018: Saniona progress to second part of Phase 2a study for Tesomet in Prader-Willi Syndrome based on positive results in adult patients

Feb 20, 2018: Soleno Therapeutics Announces Successful End-of-Phase II Meeting with FDA for DCCR in Prader-Willi Syndrome

Feb 07, 2018: Saniona: Saniona Completes Recruitment in Phase I study with new Tesomet tablet

Jan 16, 2018: Saniona initiates Phase I study with new Tesomet tablet

Jan 08, 2018: Saniona reports top line results from the Tesomet Phase 2a interim study in Prader-Willi syndrome

Jan 05, 2018: Zafgen Provides update on its Drug Candidate ZGN-1258

Dec 26, 2017: FDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Cannabidiol (CBD) Oral Solution as Investigational Treatment for Prader-Willi Syndrome

Oct 26, 2017: Saniona AB: Saniona decides to perform interim analysis of Tesomet study in patients with Prader-Willi syndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Prader-Willi Syndrome (PWS), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Prader-Willi Syndrome (PWS) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2018

Prader-Willi Syndrome (PWS) - Pipeline by ConSynance Therapeutics Inc, H2 2018

Prader-Willi Syndrome (PWS) - Pipeline by Ferring International Center SA, H2 2018

Prader-Willi Syndrome (PWS) - Pipeline by Insys Therapeutics Inc, H2 2018

Prader-Willi Syndrome (PWS) - Pipeline by LG Chem Ltd, H2 2018

Prader-Willi Syndrome (PWS) - Pipeline by Millendo Therapeutics Inc, H2 2018

Prader-Willi Syndrome (PWS) - Pipeline by OptiNose US Inc, H2 2018

Prader-Willi Syndrome (PWS) - Pipeline by Saniona AB, H2 2018

Prader-Willi Syndrome (PWS) - Pipeline by Soleno Therapeutics Inc, H2 2018

Prader-Willi Syndrome (PWS) - Pipeline by Zafgen Inc, H2 2018

Prader-Willi Syndrome (PWS) - Dormant Projects, H2 2018

Prader-Willi Syndrome (PWS) - Discontinued Products, H2 2018

List of Figures

Number of Products under Development for Prader-Willi Syndrome (PWS), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Chong Kun Dang Pharmaceutical Corp
  • ConSynance Therapeutics Inc
  • Ferring International Center SA
  • Insys Therapeutics Inc
  • LG Chem Ltd
  • Millendo Therapeutics Inc
  • OptiNose US Inc
  • Saniona AB
  • Soleno Therapeutics Inc
  • Zafgen Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll